The recombinant human cytokine interleukin-2 (rhIL-2, or aldesleukin) was originally approved as a drug for immune oncology targeting renal cell carcinoma (Klapper et al., 2008; Krieg et al., 2010). This evidence concerns the gene IL2 and renal cell carcinoma.